Get to know our clinical trials
Phase II clinical trial in patients with advanced high-grade serous or endometrioid epithelial ovarian, fallopian tube or primary peritoneal cancer who are scheduled for neoadjuvant chemotherapy and cytoreductive surgery.
THE OBJECTIVE IS TO FURTHER DETERMINE WHETHER RADSPHERIN® CAN HAVE A POSITIVE EFFECT ON DISEASE PROGRESSION IN PEOPLE WITH OVARIAN CANCER AFTER SURGICAL TREATMENT. THIS STUDY WILL ALSO FURTHER EVALUATE THE SAFETY OF RADSPHERIN®.
Cancer Center
Status
In recruitment
headquarters
Pamplona/Madrid
Early phase
Technical Summary
- Code EudraCT: 2023-508497-28-00
- Protocol number: RAD-18-003
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.